13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001844645
Total reported value
$307.8M
$307.8M
12 檔
66.0%
In Q4 2025, Pivotal bioVenture Partners Investment Advisor LLC's U.S. equity holdings reached a combined market value of $307.8M, distributed across 12 disclosed stock positions.
In Q4 2025, Pivotal bioVenture Partners Investment Advisor LLC displayed an active expansion posture, initiating 2 new positions and adding to 1 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 24.48% | -1.59% | — | |
| 2 | OCS | Oculis Holding AG | Stock-Other | 17.67% | -9.18% | -0.53% | |
| 3 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 15.34% | -0.64% | -35.55% | |
| 4 | EVMN | Evommune Inc | Stock-Other | 12.75% | -7.51% | — | |
| 5 | ZBIO | Zenas Biopharma Inc | Stock-Other | 8.31% | -0.09% | -24.01% | |
| 6 | TRVI | Trevi Therapeutics Inc | Stock-Other | 6.08% | +3.93% | — | |
| 7 | IMNM | Immunome Inc | Stock-Other | 6.08% | -0.69% | +45.77% | |
| 8 | MPLT | Maplight Therapeutics Inc | Stock-Other | 4.15% | +2.68% | — | |
| 9 | BIOA | Bioage Labs Inc | Stock-Other | 3.34% | +1.12% | — | |
| 10 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.94% | +0.06% | — | |
| 11 | ✓ | Rallybio CORP | Stock-Other | 0.64% | — | — | |
| 12 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.20% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IMNM | Immunome Inc | +2.7% | +45.77% | Add |
| 2 | BIOA | Bioage Labs Inc | +1.1% | — | Unchanged |
| 3 | ✓ | Rallybio CORP | -0.1% | — | Unchanged |
| 4 | BOLT | Bolt Biotherapeutics Inc | -0.1% | — | Unchanged |
| 5 | TRVI | Trevi Therapeutics Inc | -0.6% | — | Unchanged |
| 6 | RXRX | Recursion Pharmaceuticals-a | -0.7% | — | Unchanged |
| 7 | ZBIO | Zenas Biopharma Inc | -1.7% | -24.01% | Trim |
| 8 | PCVX | Vaxcyte Inc | -4.1% | — | Unchanged |
| 9 | OCS | Oculis Holding AG | -5.7% | -0.53% | Trim |
| 10 | ARQT | Arcutis Biotherapeutics Inc | -7.8% | -35.55% | Trim |
| 11 | EVMN | Evommune Inc | — | NEW | New buy |
| 12 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Pivotal bioVenture Partners Investment Advisor LLC reported a total U.S. public equity portfolio value of $307.8M across 12 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, OCS, ARQT) accounted for 66.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
EVMN
市值: $33.0M
Top Position Liquidated / Trimmed
OCS
前期市值: $40.4M
During Q4 2025, Pivotal bioVenture Partners Investment Advisor LLC's top holdings by market value included PCVX (24.5%)、OCS (17.7%)、ARQT (15.3%). The largest single position, PCVX, represented 24.5% of total portfolio value.
In Q4 2025, Pivotal bioVenture Partners Investment Advisor LLC made 6 total portfolio adjustments, initiating 2 new buys, adding to 1 positions, trimming 3 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.